Gilead Partners with Tubulis for Solid Tumor ADC Development in Deal Worth Up to $465M
Partnership Agreement:
Gilead Sciences has entered into an exclusive option and license agreement with Tubulis, a German biotech company, to develop an antibody-drug conjugate (ADC) candidate for a solid tumor target23.
Financial Terms:
The deal includes an upfront payment of $20M to Tubulis, with the potential for a $30M option fee and up to $415M in milestone payments, totaling up to $465M35.
Development Focus:
The collaboration aims to discover and develop an ADC candidate leveraging Tubulis' proprietary Tubutecan and Alco5 platforms for solid tumor treatment2.
Strategic Move:
This partnership marks another significant move by Gilead in the ADC field, a type of chemotherapy it has struggled to capitalize on since acquiring Kite Pharma1.
Legal Guidance:
Goodwin's Life Sciences team advised Tubulis on the agreement, highlighting the legal support behind the deal4.
Sources:
1. https://endpts.com/gilead-makes-another-adc-move-inking-up-to-415m-pact-with-tubulis/
2. https://www.nasdaq.com/articles/gilead-tubulis-partner-develop-adc-candidate-solid-tumor-target
3. https://markets.businessinsider.com/news/stocks/gilead-enters-adc-option-and-license-pact-with-tubulis-sees-dilution-1034092439
4. https://www.goodwinlaw.com/en/news-and-events/news/2024/12/announcements-lifesciences-goodwin-advises-tubulis-on-agreement-with-gilead
5. https://www.fiercebiotech.com/biotech/gilead-taps-german-biotech-tubulis-solid-tumor-adc-development-deal-worth-465m